Subgroup analysis of a phase 2A randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthma

Authors
Category Primary study
JournalAmerican Journal of Respiratory and Critical Care Medicine
Year 2012
This article has no abstract
Epistemonikos ID: 38dee90d8027d7ea45c37392e255c5505b44b04f
First added on: Feb 07, 2025